Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07674576

Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy

Chloroprocaine is a short-acting local anesthetic that allows rapid recovery and early ambulation but is currently recommended for procedures lasting 40 minutes or less.

Dexamethasone is commonly used during anesthesia for the prevention of postoperative nausea and vomiting and has also been shown to prolong the duration of analgesia and sensory block after regional anesthesia.

Dexamethasone may therefore extend the duration of chloroprocaine spinal anesthesia, potentially allowing its use for longer surgical procedures while maintaining the benefits of rapid postoperative recovery.

This study aims to evaluate whether intravenous dexamethasone can prolong the effects of spinal anesthesia performed with chloroprocaine in adults undergoing knee arthroscopy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

About this study

This is a monocenter, prospective, randomized (1:1 ratio), controlled, parallel-group, double-blind, phase III superiority trial assessing the efficacy and the safety of IV dexamethasone for prolonging sensory block in patients undergoing knee arthroscopy under spinal anesthesia with chloroprocaine.

Participants will be randomly allocated into two groups:

  • Group CHLORO (control group): Patients will receive spinal anesthesia with chloroprocaine 40mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.
  • Group CHLORODEX (experimental group): Patients will receive spinal anesthesia with chloroprocaine 40 mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of dexamethasone at a dose of 0.15 mg/Kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.

To ensure blinding, study infusions (saline or dexamethasone) will be prepared in identical 100 mL bags and labelled by a pharmacy staff member or an "outside protocol" healthcare professional (physician or nurse) not involved in patient care or assessment.

The infusion will start approximately 10-15 minutes before the spinal punction.

In the operating room, patients will receive standard perioperative care for spinal anesthesia, including placement of a peripheral intravenous line, supplemental low-flow oxygen therapy to maintain SpO₂ > 93%, continuous hemodynamic monitoring, and strict aseptic precautions. Analgesic premedication with paracetamol combined with either ketoprofen or celecoxib will be administered according to institutional practice.

Spinal anesthesia will be performed with the patient in a semi-sitting position via the L3-L4 or L4-L5 interspace using a 25G x 80mm Sprotte needle. After cerebrospinal fluid reflux, 40 mg of chloroprocaine without adjuvant will be injected intrathecally, and patients will then be positioned in the supine position for the procedure.

Knee arthroscopy will be performed according to standard surgical practice, without any modification of the surgical procedure for study purposes.

No additional sedation or analgesia will be administered during the procedure. In the event of failure of spinal anesthesia or early recovery of sensation, conversion to general anesthesia or deep sedation may be performed at the discretion of the anesthesiologist, depending on the clinical situation.

Postoperatively, multimodal analgesia will be initiated according to the institutional protocol, combining paracetamol, nefopam, and either ketoprofen or celecoxib, with morphine administered if necessary.

Sensory and motor blocks will be assessed every 5 minutes after spinal puncture until regression of two dermatomes and then every 10 minutes until recovery of four dermatomes and complete motor function (maximum until hospital discharge).

Motor block will be assessed using the Bromage score and sensory block will be assessed using the Pin Prick test and the cold test.

The primary objective of the study is to evaluate the efficacy of intravenous dexamethasone in prolonging sensory block following spinal anesthesia with chloroprocaine, as assessed by the time from intrathecal injection to regression of sensory block by two dermatomes from the highest level of sensory block achieved, as measured by the pin-prick test.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Undergoing knee arthroscopy lasting ≤ 40 minutes requiring spinal anesthesia (diagnostic arthroscopy or meniscal surgery),
  • Signed written informed consent form,
  • Affiliation to a social security system,
  • Negative pregnancy test on the day of procedure for non-menopausal patients.

Exclusion criteria

  • Contraindications to spinal anesthesia with intrathecal chloroprocaine
  • History of diabetes,
  • Pre-existing peripheral neuropathy,
  • American Society of Anesthesiologists (ASA) physical status IV,
  • Contraindication to dexamethasone,
  • Hypersensitivity of any drug used in this study,
  • Long-term oral corticosteroid therapy,
  • Chronic opioid use,
  • Chronic pain syndromes,
  • Contraindications to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (Ketoprofen, Celecoxib)
  • Need for a peripheral nerve block in addition to spinal anesthesia (e.g. knee ligamentoplasty),
  • Mental or linguistic inability to understand the study,
  • Patients under legal protection (guardianship, curatorship or safeguard of justice),
  • Patients currently included or planning to be included in another interventional study,
  • Pregnant or breastfeeding women,
  • Women of childbearing potential not using effective contraception.

Treatment and study plan

Sodium chloride 0.9%

Drug

IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes

Dexamethasone

Drug

IV infusion of dexamethasone at a dose of 0.15 mg/kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes

Chloroprocaine Injection [Clorotekal]

Drug

Spinal anesthesia with chloroprocaine 40 mg

Primary outcomes

  1. Time to regression of sensory block by two dermatomes (pin-prick test)

    Time frame: Up to 2 hours following spinal anesthesia

    Time (in minutes) from the spinal puncture to the first assessment at which the sensory block has regressed by two dermatomes from the maximum (highest/most cephalad) dermatome level of sensory block achieved after the puncture, assessed with the pin-prick test. Sensory testing will be performed every 5 minutes until two-dermatome regression is observed. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.

Secondary outcomes

  1. Time to complete resolution of motor block

    Time frame: Up to 8 hours following spinal anesthesia

    Time (in minutes) from the spinal puncture to complete recovery of motor block, assessed by the Modified Bromage Scale (0-3: 0 = full flexion of hip, knee, and ankle; 1 = inability to raise extended leg; 2 = inability to flex knee; 3 = no movement of hip, knee, or ankle). Motor block will be assessed every 5 minutes after the spinal puncture until regression of the sensory block by two dermatomes, and then every 10 minutes until complete motor recovery (Bromage 0).

  2. Time to regression of sensory block by four dermatomes (pin-prick test)

    Time frame: Up to 8 hours following spinal anesthesia

    Time (in minutes) from the spinal puncture to regression of four dermatomes from the highest dermatome level of sensory block achieved after the puncture. Sensory block will be assessed using the pin-prick test every 5 minutes after the spinal puncture until regression by two dermatomes, and then every 10 minutes until regression by four dermatomes. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.

  3. Maximum sensory block level

    Time frame: Up to 30 minutes following spinal anesthesia

    Highest dermatome level of sensory block achieved after the spinal puncture (pin-prick test).

  4. Time to maximum sensory block level

    Time frame: Up to 30 minutes following spinal anesthesia

    Time (in minutes) from the spinal puncture to the highest blocked dermatome (pin-prick test).

  5. Need for additional anesthetic procedure

    Time frame: From spinal anesthesia to the end of surgery

    Whether an additional anesthetic procedure was required during surgery, including sedation or conversion to general anesthesia

  6. Time to regression of sensory block by two dermatomes (cold test)

    Time frame: Up to 2 hours following spinal anesthesia

    Time (in minutes) from spinal puncture to two dermatome sensory regression assessed by a standardized cold test

  7. Incidence of hypotension

    Time frame: From spinal anesthesia to 24 hours after surgery

    Any episode of hypotension, defined as a systolic blood pressure (SBP) < 90 mmHg and/or a mean arterial pressure (MAP) < 65 mmHg and/or a decrease in blood pressure ≥ 30% from baseline

  8. Incidence of bradycardia

    Time frame: From spinal anesthesia to 24 hours after surgery

    Any episode of bradycardia defined as a heart rate (HR) < 50 bpm

  9. Incidence of nausea

    Time frame: From spinal anesthesia to 24 hours after surgery

    Any episode of nausea reported by the patient or nursing team

  10. Incidence of vomiting

    Time frame: From spinal anesthesia to 24 hours after surgery

    Any episode of vomiting reported by the patient or nursing team

  11. Incidence of pruritus

    Time frame: From spinal anesthesia to 24 hours after surgery

    Any episode of pruritus reported by the patient or nursing team

  12. Incidence of urinary retention

    Time frame: From spinal anesthesia to 24 hours after surgery

    Any episode of urinary retention reported by the patient or nursing team

  13. Maximal pain score in the PACU

    Time frame: Up to 6 hours following spinal anesthesia

    Maximal pain score collected in the PACU using a Numeric Rating Scale (NRS-Pain) ranging from 0 to 10 (0= no pain; 10= extreme pain).

  14. Total opioid consumption

    Time frame: From spinal anesthesia to 24 hours after surgery

    Total opioid consumption, converted to oral morphine equivalents (OME, mg) from the intraoperative period to 24 hours postoperatively, including opioid use at home as reported during the Day 1 follow-up

  15. Pain intensity

    Time frame: From spinal anesthesia to 24 hours after surgery

    Pain intensity at rest and during movement will be assessed using a Numeric Rating Scale (NRS-Pain) ranging from 0 to 10 (0= no pain; 10= extreme pain). Pain scores will be recorded intraoperatively (H0)in the PACU (H1), during ambulatory hospitalization (H3 and H6), and at home until Day-1 (H9, H12 and H24).

  16. Duration of surgery

    Time frame: Intraoperative period

    Time (in minutes) between the skin incision and the last suture

  17. Incidence of post-puncture headache

    Time frame: From spinal anesthesia to 24 hours after surgery

    Any episode of headache reported by the patient or nursing team

Study contacts

Contact information is provided by the study sponsor or research team.

Sébastien BLOC, MD

CONTACT

[email protected]

01 44 14 11 11

Sponsors and collaborators

Lead sponsor

CMC Ambroise Paré

Other

Registry information

Official study title

Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy: a Double-blind, Randomized, Controlled Trial

Acronym: CHLORODEX

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jun 29, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.